Thrombotic risk in the antiphospholipid syndrome

Area of Science:

• Rheumatology
• Hematology
• Immunology

Background:

• Antiphospholipid syndrome (APS) involves thrombosis and pregnancy morbidity due to antiphospholipid antibodies (aPL).
• APS patients have a significant risk of recurrent thrombosis, often persisting despite anticoagulant treatment.
• Current anticoagulant strategies for APS, especially for arterial and recurrent thrombosis, lack definitive guidelines.

Purpose of the Study:

• To review the thrombotic risk profiles in antiphospholipid syndrome.
• To discuss the controversies surrounding optimal anticoagulant therapy for APS.
• To highlight the increased risk associated with triple antiphospholipid antibody positivity.

Main Methods:

• Literature review of antiphospholipid syndrome, thrombosis, and anticoagulation.
• Analysis of risk factors, including specific antiphospholipid antibody profiles.
• Discussion of clinical implications for treatment strategies.

Main Results:

• Patients with triple aPL positivity (lupus anticoagulant, anticardiolipin, anti-β2 glycoprotein I antibodies) show a higher thrombosis risk.
• Recurrent thrombosis can occur in APS patients despite ongoing anticoagulant therapy.
• Risk stratification may aid in tailoring anticoagulant therapy duration and intensity.

Conclusions:

• Recognizing varied thrombotic risk in APS is crucial for clinical decision-making.
• Further research is needed to optimize anticoagulant and non-anticoagulant therapies for APS.
• Personalized risk assessment can guide the management of APS-related thrombosis.